Asieris’ Multinational Phase III Clinical Trial for the Non-Surgical Treatment of HSIL Has Completed Enrollment August 9, 2022
The First Domestic Case in Boao, Ushering in a New Option for Diagnosing Bladder Cancer August 8, 2022
Asieris to publish the study protocol of Cevira® as a novel treatment in patients with high grade squamous intraepithelial lesion (HSIL) on BMJ Open June 9, 2022
Asieris to present a study protocol of APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy (NAC) for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting May 27, 2022
World’s First Patient Dose Administered in Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients January 4, 2022
